首页> 外文期刊>Drug Design, Development and Therapy >Amsacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics
【24h】

Amsacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics

机译:装载Amsacrine类似物的固体脂质纳米颗粒可解决注射给药的不溶性:表征和药代动力学

获取原文
           

摘要

Amsacrine analog is a novel chemotherapeutic agent that provides potentially broad antitumor activity when compared to traditional amsacrine. However, the major limitation of amsacrine analog is that it is highly lipophilic, making it nonconductive to intravenous administration. The aim of this study was to utilize solid lipid nanoparticles (SLN) to resolve the delivery problem and to investigate the biodistribution of amsacrine analog-loaded SLN. Physicochemical characterizations of SLN, including particle size, zeta potential, entrapment efficiency, and stability, were evaluated. In vitro release behavior was also measured by the dialysis method. In vivo pharmacokinetics and biodistribution behavior of amsacrine analog were investigated and incorporated with a non invasion in vivo imaging system to confirm the localization of SLN. The results showed that amsacrine analog-loaded SLN was 36.7 nm in particle size, 0.37 in polydispersity index, and 34.5±0.047 mV in zeta potential. More than 99% of amsacrine analog was successfully entrapped in the SLN. There were no significant differences in the physicochemical properties after storage at room temperature (25°C) for 1 month. Amsacrine analog-loaded SLN maintained good stability. An in vitro release study showed that amsacrine analog-loaded SLN sustained a release pattern and followed the zero equation. An in vivo pharmacokinetics study showed that amsacrine analog was rapidly distributed from the central compartment to the tissue compartments after intravenous delivery of amsacrine analog-loaded SLN. The biodistribution behavior demonstrated that amsacrine analog mainly accumulated in the lungs. Noninvasion in vivo imaging system images also confirmed that the drug distribution was predominantly localized in the lungs when IR-780-loaded SLN was used.
机译:Amsacrine类似物是一种新型化学治疗剂,与传统Amsacrine相比具有潜在的广泛抗肿瘤活性。然而,amsacrine类似物的主要局限性是它具有高度亲脂性,使其对静脉内给药不敏感。这项研究的目的是利用固体脂质纳米颗粒(SLN)来解决传递问题,并研究负载Amsacrine类似物的SLN的生物分布。评估了SLN的理化特性,包括粒径,ζ电势,截留效率和稳定性。还通过透析方法测量了体外释放行为。研究了amsacrine类似物的体内药代动力学和生物分布行为,并将其与体内非侵入性成像系统结合以确认SLN的定位。结果表明,负载氨丝氨酸类似物的SLN的粒径为36.7 nm,多分散指数为0.37,ζ电位为34.5±0.047 mV。超过99%的amsacrine类似物已成功地包埋在SLN中。在室温(25°C)下保存1个月后,其理化性质无显着差异。负载Amsacrine类似物的SLN保持良好的稳定性。一项体外释放研究表明,负载氨丝氨酸类似物的SLN维持释放模式,并遵循零方程。体内药代动力学研究表明,在静脉内递送负载有氨丝氨酸类似物的SLN后,氨丝氨酸类似物迅速从中央室分布到组织室。生物分布行为表明,氨水星类似物主要在肺中积累。非侵入性体内成像系统图像还证实,当使用装载IR-780的SLN时,药物分布主要位于肺部。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号